140 related articles for article (PubMed ID: 32582542)
1. Clinical Evaluation of Serum Tumor Markers in Patients With Advanced-Stage Non-Small Cell Lung Cancer Treated With Palliative Chemotherapy in China.
Abbas M; Kassim SA; Habib M; Li X; Shi M; Wang ZC; Hu Y; Zhu HL
Front Oncol; 2020; 10():800. PubMed ID: 32582542
[No Abstract] [Full Text] [Related]
2. Clinical evaluation of plasma coagulation parameters in patients with advanced-stage non-small cell lung cancer treated with palliative chemotherapy in China.
Abbas M; Kassim SA; Wang ZC; Shi M; Hu Y; Zhu HL
Int J Clin Pract; 2020 Dec; 74(12):e13619. PubMed ID: 32726491
[TBL] [Abstract][Full Text] [Related]
3. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC).
Cedrés S; Nuñez I; Longo M; Martinez P; Checa E; Torrejón D; Felip E
Clin Lung Cancer; 2011 May; 12(3):172-9. PubMed ID: 21663860
[TBL] [Abstract][Full Text] [Related]
4. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
[TBL] [Abstract][Full Text] [Related]
5. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
Ma S; Shen L; Qian N; Chen K
Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
[TBL] [Abstract][Full Text] [Related]
6. [Exploration of the rational therapeutic regimen for advanced lung cancer patients with mild tumor enlargement].
Zhang XL; Wang XY; Zhang CC; Yang J; Yuan XH; Li K
Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):775-782. PubMed ID: 29061023
[No Abstract] [Full Text] [Related]
7. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
8. Dynamic monitoring of serum tumor markers as prognostic factors in patients with advanced non-small-cell lung cancer treated with first-line immunotherapy: a multicenter retrospective study.
Yang X; Xiao Y; Zhou Y; Deng H; Yuan Z; Dong L; Lan J; Hu H; Huang J; Huang S
Ther Adv Med Oncol; 2023; 15():17588359231206282. PubMed ID: 37920256
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer.
Webb A; Scott-Mackie P; Cunningham D; Norman A; Andreyev J; O'Brien M; Bensted J
Ann Oncol; 1995 Jul; 6(6):581-7. PubMed ID: 8573538
[TBL] [Abstract][Full Text] [Related]
10. Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Cui S; Xiong L; Lou Y; Shi H; Gu A; Zhao Y; Chu T; Wang H; Zhang W; Dong L; Jiang L
J Thorac Dis; 2016 Jan; 8(1):68-78. PubMed ID: 26904214
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic factors in patients with stage III and IV non-small cell lung cancer].
Song LH; Song XR; Liu MQ; Zhang XQ; Zheng L; Li XJ; Liu PX
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):345-8. PubMed ID: 15312344
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive value of serum carcinoembryonic antigen levels in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutations and receiving tyrosine kinase inhibitors.
Zhao XM; Zhao J; Xing KL; Sun S; Luo ZG; Wang HJ; Wang JL; Chang JH; Wu XH
Oncotarget; 2017 Sep; 8(41):70865-70873. PubMed ID: 29050327
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
Koch A; Fohlin H; Sörenson S
J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of carcinoembryonic and carbohydrate antigens as cancer biomarkers to monitor palliative chemotherapy in advanced stage gastric cancer.
Abbas M; Ahmed A; Khan GJ; Baig MMFA; Naveed M; Mikrani R; Cao T; Naeem S; Shi M; Dingding C
Curr Probl Cancer; 2019 Feb; 43(1):5-17. PubMed ID: 30172422
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
16. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
[TBL] [Abstract][Full Text] [Related]
17. [Utility of Multiple Increased Lung Cancer Tumor Markers in Treatment of Patients with Advanced Lung Adenocarcinoma].
Peng Y; Wang Y; Hao X; Li J; Liu Y; Wang H
Zhongguo Fei Ai Za Zhi; 2017 Oct; 20(10):690-694. PubMed ID: 29061216
[TBL] [Abstract][Full Text] [Related]
18. Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Suh KJ; Keam B; Kim M; Park YS; Kim TM; Jeon YK; Kim DW; Chung DH; Kim YW; Heo DS
Clin Lung Cancer; 2016 Jul; 17(4):245-252.e1. PubMed ID: 26719155
[TBL] [Abstract][Full Text] [Related]
19. Declines in serum CYFRA21-1 and carcinoembryonic antigen as predictors of chemotherapy response and survival in patients with advanced non-small cell lung cancer.
Yang L; Chen X; Li Y; Yang J; Tang L
Exp Ther Med; 2012 Aug; 4(2):243-248. PubMed ID: 22970029
[TBL] [Abstract][Full Text] [Related]
20. Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Du G; Yang Y; Zhang Y; Sun T; Liu W; Wang Y; Li J; Zhang H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):893-904. PubMed ID: 23355038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
